Karyopharm Therapeutics Inc.
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
Last updated:
Abstract:
The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Status:
Application
Type:
Utility
Filling date:
25 Apr 2019
Issue date:
19 Mar 2020